Login to Your Account

Pharma: Clinic Roundup

Monday, August 13, 2012

• Pfizer Inc., of New York, reported that the combination of its Torisel (temsirolimus) and bevacizumab (Avastin, Genentech Inc.) failed to demonstrate superiority to bevacizumab plus interferon-alfa-2a in progression-free survival in the Phase III INTORACT trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription